Document resource
Objective/Background To evaluate the safety of intravenous edaravone administered to patients with ALS referred to a national home infusion service.ALS is a neurodegenerative condition that causes progressive muscle weakness. Edaravone is a free radical scavenger which reduces oxidative stress, however, its mechanism of action in ALS is unknown. Two 6-month, randomised, placebo-controlled, double-blind studies showed edaravone slowed functional decline in people with ALS. Edaravone was approved by the Therapeutic Goods Administration (TGA) in January 2023 and in December 2024 received agreement for listing on the Pharmaceutical Benefits Scheme (PBS). It is awaiting addition to the PBS but is available through the TGA Special Access Scheme.Method Electronic health records of patients referred to a national home infusion service were reviewed. Data was collated on demographics, infusional-related reactions (iRRs), use of hypersensitivity-anaphylaxis standard orders (HASO), and transfer to hospital.Results Three patients received 225 infusions of intravenous edaravone at home. Pt AC, 57yo F received 31 doses, via a PICC line, with mild flushing post infusion. Pt DW, 38 yo M received 184 doses, via a port with no iRRs. DH, 57 yo M received 10 doses, via an IV cannula with no iRRs. No patient required use of HASO or was transferred to hospital.Conclusion Although the PBS indication is for patients who are independent in activities of daily living and where treatment is initiated within 2-years of disease onset, treatment at home alleviates the stress of travelling to hospital for treatment. Edaravone infusions at home are safe.